"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

Share repurchases have amplified shareholder returns as its annual earnings per share growth of 34.7% exceeded its revenue ...

On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

As we continue to advance our Axiomer ADAR-mediated RNA editing platform and pipeline, ProQR is entering a pivotal phase of growth and ...

Eli Lilly (LLY) stock dropped by 0.22%, underperforming the S&P 500’s 0.49% gain. Over the past month, the stock has fallen 4 ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

In the biotechnology and chemical spaces, genus claims are often sought by patent applicants to protect not only a specific product of interest, ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.